The MET oncogene encodes an unconventional receptor tyrosine kinase with pleiotropic functions: it initiates and sustains neoplastic transformation when genetically altered ('oncogene addiction') and fosters cancer cell survival and tumour dissemination when transcriptionally activated in the context of an adaptive response to adverse microenvironmental conditions ('oncogene expedience'). Moreover, MET is an intrinsic modulator of the self-renewal and clonogenic ability of cancer stem cells ('oncogene inherence'). Here, we provide the latest findings on MET function in cancer by focusing on newly identified genetic abnormalities in tumour cells and recently described non-mutational MET activities in stromal cells and cancer stem cells. We discuss how MET drives cancer clonal evolution and progression towards metastasis, both ab initio and under therapeutic pressure. We then elaborate on the use of MET inhibitors in the clinic with a critical appraisal of failures and successes. Ultimately, we advocate a rationale to improve the outcome of anti-MET therapies on the basis of thorough consideration of the entire spectrum of MET-mediated biological responses, which implicates adequate patient stratification, meaningful biomarkers and appropriate clinical end points.

Known and novel roles of the MET oncogene in cancer: A coherent approach to targeted therapy

Comoglio, Paolo M.;Trusolino, Livio
Co-last
;
Boccaccio, Carla
Co-last
2018

Abstract

The MET oncogene encodes an unconventional receptor tyrosine kinase with pleiotropic functions: it initiates and sustains neoplastic transformation when genetically altered ('oncogene addiction') and fosters cancer cell survival and tumour dissemination when transcriptionally activated in the context of an adaptive response to adverse microenvironmental conditions ('oncogene expedience'). Moreover, MET is an intrinsic modulator of the self-renewal and clonogenic ability of cancer stem cells ('oncogene inherence'). Here, we provide the latest findings on MET function in cancer by focusing on newly identified genetic abnormalities in tumour cells and recently described non-mutational MET activities in stromal cells and cancer stem cells. We discuss how MET drives cancer clonal evolution and progression towards metastasis, both ab initio and under therapeutic pressure. We then elaborate on the use of MET inhibitors in the clinic with a critical appraisal of failures and successes. Ultimately, we advocate a rationale to improve the outcome of anti-MET therapies on the basis of thorough consideration of the entire spectrum of MET-mediated biological responses, which implicates adequate patient stratification, meaningful biomarkers and appropriate clinical end points.
18
6
341
358
http://www.nature.com/cancer/
Oncology; Cancer Research
Comoglio, Paolo M.*; Trusolino, Livio; Boccaccio, Carla
File in questo prodotto:
File Dimensione Formato  
Nat rev can.pdf

Accesso riservato

Descrizione: Nat rev can_riservato
Tipo di file: PDF EDITORIALE
Dimensione 4.06 MB
Formato Adobe PDF
4.06 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Nat rev can_2018.pdf

Accesso aperto con embargo fino al 01/01/2019

Descrizione: Nat rev can_aperto
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 661.98 kB
Formato Adobe PDF
661.98 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1670498
Citazioni
  • ???jsp.display-item.citation.pmc??? 105
  • Scopus 162
  • ???jsp.display-item.citation.isi??? 156
social impact